Clinical Trial Update: A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares long-acting methylphenidate (Concerta) to placebo for memory loss associated with HIV dementia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Dementia

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: University of California, Los Angeles | Conditions: HIV Dementia | Phase 3 | Status: UNKNOWN